severe RRMS [4] . Subsequently, teriflunomide was approved in the USA in September 2012
and in Europe in March 2013 [5, 6] . Dimethyl fumarate (DMF; BG-12) was approved in the USA in March 2013 and recently in Europe as well [7, 8] . DMTs aim to reduce the frequency and severity of relapses, extend the time intervals between relapses and slow progression to permanent disability [2] . To assess these treatment goals, annualized relapse rates (ARRs) or time to first relapse and disability progression, as measured by the expanded disability status scale (EDSS), are the primary clinical endpoints of phase 3 studies of therapies for RRMS, with magnetic resonance imaging (MRI) measures of disease activity and burden (CNS lesions) as secondary endpoints. Oral therapies have been shown to offer benefits with regard to these clinical and MRI outcomes when compared with placebo in phase 3 trials [9] [10] [11] [12] [13] . The clinical efficacy of these therapies over traditional injectable DMTs has been demonstrated for fingolimod in the trial assessing injectable interferon versus FTY720 oral in RRMS (TRANSFORMS) [14] , and for the 7 mg dose (but not the 14 mg dose) of teriflunomide in the teriflunomide and Rebif (TENERE) trial [15] . were free from disease activity than individuals receiving placebo (18% and 23% vs. 14%; P = 0.0293 and P = 0.0002, respectively) [23] .
There are no head-to-head controlled trials comparing the efficacy of the different oral DMTs. This is an area of much interest to neurologists and healthcare decision makers; therefore, several indirect treatment comparisons have recently been performed. Of these, two studies have compared fingolimod with teriflunomide [24, 25] . A network metaanalysis (NMA) found a significantly lower ARR with fingolimod than with teriflunomide 14 mg, but no significant difference in the proportion of patients with 3-month confirmed disability progression [24] . A separate NMA study found no statistically significant differences between fingolimod and teriflunomide 7 or 14 mg on measures of freedom from relapse and disease progression [25] . A recent study has additionally compared fingolimod with DMF using an NMA approach and found no significant differences in ARR or in the proportion of patients with disability progression lasting at least 3 months [26] . Standard NMA methods may be susceptible to bias because of differences in trial populations and methodologies. The placebocontrolled trials of these oral MS therapies are not sufficiently similar and differences between the trials, including differences in patient populations, endpoint definitions and methods for dealing with non-completers, have not been taken into account in any of the NMAs of these therapies performed to date. Subgroup and post hoc analyses of the phase 3 trials of DMTs have demonstrated that differences in patient baseline characteristics influence the observed effect of DMTs on ARRs and disability progression [14, 27] , and that the application of different definitions of disability progression has a large impact on disability outcomes [28] . Therefore, it is important to adjust for these potentially confounding factors when assessing the comparative efficacy of these oral DMTs. Limited methodology exists to perform this type of adjusted comparison.
Therefore, we developed a statistical modeling approach to compare treatment effects that adjusted for differences in patient characteristics and methodologies across the MS trials and allowed for the use of a combination of individual patient-and population-level data, thus permitting the utilization of all available data for these treatments [29] [30] [31] [32] . Here, we have compared the effectiveness of oral therapies for MS (fingolimod 0.5 mg, DMF 240 mg twice daily and teriflunomide 7 or 14 mg) for achieving NEDA status. Our modeling approach uses all publicly available data for oral therapies and individual patient-level data from the phase 3 placebo-controlled trials of fingolimod.
METHODS

Clinical Trials
The methodological details of the five doubleblind, randomized, controlled, phase 3 trials for fingolimod (FREEDOMS and FREEDOMS II),
DMF
(DEFINE and CONFIRM) and teriflunomide (TEMSO) are described elsewhere [9] [10] [11] [12] [13] . This analysis used data for the placebo groups of these trials and the following treatment groups: fingolimod 0.5 mg, DMF 240 mg twice daily and teriflunomide 7 and 14 mg. Comparisons with DMF 240 mg three times daily were also performed. The number of patients randomized to each group and the differences in inclusion and exclusion criteria among trials are described in Supplementary Material S1. As data for this study were obtained from these trials and do not involve any new studies of human or animal subjects, ethical approval or participant's informed consent was 
NEDA Outcomes
NEDA was evaluated as the proportion of patients free from relapses, free from 3-month confirmed disability progression, free from gadolinium (Gd)-enhancing T1 lesions and free from new or newly enlarged T2 lesions.
Using a similar methodology to the post hoc analyses of the placebo-controlled, phase 3 trial of natalizumab, AFFIRM [19] , these individual components were combined to assess NEDA in three composite measures. The clinical composite of NEDA measured freedom from relapses and 3-month confirmed disability progression. The MRI composite of NEDA measured freedom from Gd-enhancing T1 lesions and new or newly enlarged T2 lesions.
The overall composite or overall NEDA measured freedom from all of these disease outcomes.
In the FREEDOMS trials, if patients did not complete the trial and were disease free at their last study visit, they were counted as having achieved NEDA status [21] . This method was also assumed for the TEMSO trial where all patients who were randomized were included in the analysis, so we assumed that a disease-free non-completer was counted as having achieved NEDA status. In the DEFINE and CONFIRM trials, it was assumed that non-completers were removed from the analysis if they were disease free because these analyses were performed by the same investigators as the original AFFIRM analyses, which excluded these patients from analyses [21] . In the absence of published information from the DEFINE, CONFIRM and TEMSO trials it was assumed that all patient visits (i.e., both scheduled and unscheduled) were assessed for presence of disease activity.
Statistical Modeling
Models were built to estimate the efficacy of fingolimod in improving the probability (and thereby relative risk [RR] compared with placebo) of achieving NEDA status, and to compare the efficacy with that of other DMTs.
Individual patient data from the pooled fingolimod phase 3 trials, FREEDOMS and FREEDOMS II, were used to build binomial regression models to estimate the proportion of patients achieving NEDA status. Data from FREEDOMS and FREEDOMS II were pooled by including a study-level stratifying variable. For each component and composite measure, the efficacy of fingolimod was estimated by reanalyzing the individual patient data from the fingolimod phase 3 trials using methodologies from studies of other oral therapies (adjusted only for endpoint definitions and how trial non-completers contributed to the analyses). Owing to differences in definitions and methodologies between the trials, two slightly different sets of models, termed 'estimated' models, were constructed; one for fingolimod versus DMF and another for fingolimod versus teriflunomide. Models for the DMF comparisons were based on the same definitions of disability progression used in the DEFINE and CONFIRM trials for patients with an EDSS score of 0 at baseline (i.e., 1.5-point change), whereas models for teriflunomide comparisons utilized the same definition as originally used in the FREEDOMS study for patients with an EDSS score of 0 at baseline (i.e., 1-point change). The outcomes in the models also took into account differences in the methods of dealing with noncompleters across the various trials, with disease-free patients in FREEDOMS excluded from the models for the DMF comparisons if they did not complete the trial (as assumed in the DEFINE and CONFIRM trials). Thus, these estimates took into account methodological differences between trials and were termed the 'estimated' RRs of achieving NEDA status. The RR of achieving NEDA status for fingolimod versus placebo and for DMF or teriflunomide versus placebo was combined using the method proposed by Bucher et al. [33] to assess the RR of achieving NEDA status for fingolimod versus DMF or teriflunomide. The need for different adjustments to compare fingolimod with DMF and teriflunomide prevented the use of an NMA approach [34] , and separate indirect comparisons are needed to indirectly compare the estimated RRs of achieving NEDA status for fingolimod versus DMF and teriflunomide.
Because application of the indirect comparison method proposed by Bucher et al. [33] to the treatment effect estimates requires the assumption that patient characteristics do not influence the treatment effect, we extended the method by building further models, based on the estimated models, to adjust for possible differences in baseline characteristics between the studies. In each set of estimated models, which accounted for differences in methodologies across trials, two models were constructed for each component and composite measure; an initial and a final model, in which individual patient data from the FREEDOMS trials were used to estimate the contribution of baseline characteristics to measures of NEDA.
The prediction method for these initial and final models is described in Supplementary Material S2. Initial models were built by including pre-specified baseline covariates as main and treatment interaction (i.e., potential treatment modifier) effects. Covariates likely to modify the treatment effect were selected based on the results of previous subgroup analyses of FREEDOMS [35] and AFFIRM [36] , as well as clinical expert opinion. was performed in three steps ( Fig. 1) . First, models were used to predict the RR of achieving NEDA status for fingolimod versus placebo in an average patient in a pooled DEFINE and CONFIRM population, and in the TEMSO population (termed 'predicted' models and 'predicted' RRs, respectively). Second, the estimated RR of achieving NEDA status for DMF versus placebo in the pooled DEFINE and CONFIRM population was calculated using a fixed-effect inverse variance-weighted method of the RRs from each study, a standard method for pooling outcomes from studies that provides a weighted average of estimates. The RRs from each study were found from data in
Havrdova et al. [20] reporting the probabilities of patients achieving NEDA status in each arm, with the variance of these probabilities calculated from the sample size in each arm, excluding disease-free patients who did not complete the study. Because this number is not reported, we estimated it assuming that noncompleters had the same likelihood of being disease free as those who completed the trial.
This is likely to be a conservative assumption;
in the FREEDOMS study, non-completers were less likely to be disease free than completers, leading to the sample size being reduced too much and an inflated variance of the pooled RR estimate. Similar calculations for estimating the RR of achieving NEDA status were performed for teriflunomide versus placebo in the TEMSO population using results from Freedman et al. [23] . Third, the estimated RR 
Compliance With Ethics Guidelines
The analysis in this article is based on previously conducted studies, and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
Patient Baseline Characteristics
Patient baseline demographics and disease characteristics in the pooled FREEDOMS and FREEDOMS II, pooled DEFINE and CONFIRM, and TEMSO populations are compared in Final models selected baseline characteristics that were most predictive of the outcome using a stepwise algorithm that used the Akaike information criterion as the metric to retain the best model. FREEDOMS FTY720 research evaluating effects of daily oral therapy in multiple sclerosis, RR relative risk (Fig. 2) .
Baseline Covariates Selected for Inclusion in the Final Models
The effect of each covariate included in the initial models on the predicted clinical, MRI and overall composite measures for fingolimod versus placebo was explored by changing them one at a time. To demonstrate the effect of covariates on predicting the efficacy of fingolimod, the clinical composite measure is used as an example. In models for the DMF comparisons, age and previous DMT use were found to be the best predictors of no evidence of clinical disease activity using AIC selection, whereas age was found to be the only predictor of no evidence of clinical disease activity in the models for the teriflunomide comparison. The covariates included in the initial and final models for each component measure are shown in Supplementary Material S4 and Fig. 3 , respectively.
Final Model Predictions
The covariates included in the final models can predict the efficacy of fingolimod versus placebo in an alternative trial population. 
EDSS at BL=4+
Number of relapses at BL=1
Number of relapses at BL=2
Number of Gd T1 lesions at BL=0
Number of Gd T1 lesions at BL=2 Volume of T2 lesions at baseline was not included in the initial model for the teriflunomide analysis, and EDSS-defined progression was reported differently (0-3.5 instead of 0-1.5 in the DMF analysis). BL baseline, DMF dimethyl fumarate, EDSS expanded disability status scale, Gd gadolinium, MRI magnetic resonance imaging, MS multiple sclerosis, NEDA no evidence of disease activity, RR relative risk from the trial populations of DEFINE and CONFIRM, and TEMSO. The predicted RRs for fingolimod versus placebo in an average individual from each of these trial populations were marginally increased or similar to estimated RRs for fingolimod in the pooled FREEDOMS population for the three composite measures of NEDA (Fig. 2, rows 1 (Fig. 4, rows 1, 3 and 5) and predicted values for fingolimod (Fig. 4, rows Does not take into account differences in patient population, endpoint definitions and ways of dealing with non-completers between trials and does not make use of individual patient-level data Differences in patient populations could be accounted for using metaregression by including study-level treatment-covariate interactions [45] , but adjustments at the study level can be susceptible to the ecological fallacy, where the relationship between outcome and covariate may not be the same at the study and individual level Differences in trial methodology could be accounted for using subanalyses but this requires a larger number of studies than is available in the present case to enable estimation of the random effects assuming that there is heterogeneity in treatment effect between studies [46]
Mixed treatment comparison using individual and summary level patient data [47] Enables the use of individual patient data and adjustment for patient populations, but it does not take into account differences in endpoint definitions or the different ways of dealing with non-completers This methodology can also be susceptible to ecological fallacy, require a random effects model and a separate analysis to adjust for endpoint definitions or the different ways of dealing with non-completers
Bucher pair-wise indirect comparison [33] Enables endpoint definitions or the different ways of dealing with noncompleters to be adjusted for, but does not make use of individual patient data and adjust for patient populations This methodology can be built on to adjust for patient characteristics and use individual patient data as demonstrated in our study
Matching-adjusted indirect comparison [31] Enables the use of individual patient data, adjustment for patient populations and trial methodology. This methodology uses individual patient data from trials of one treatment to match baseline summary statistics reported from trials of another treatment
This method adjusts for a predefined set of patient baseline characteristics and may over-fit the prediction model. This approach may not have sufficient power for all treatments being assessed While alternate modeling approaches are possible (see Table 2 ), these methods are less suitable because they do not allow for all of the following to be appropriately achieved: (1) controlling for differences in patient populations; (2) accounting for differences in endpoint definitions; (3) accounting for the way in which non-completers are dealt with; and (4) using individual patient data where they are available. For example, a Bayesian mixed treatment comparison has been used to compare the efficacy of teriflunomide with other approved DMTs in the treatment of MS [24] . Mixed treatment comparisons using Poisson, mixed-log binomial, time-to-event and continuous models have been used to compare the efficacy and safety of DMF with other approved DMTs including fingolimod. However, these analyses could not adjust for differences in trial methodology or endpoint definitions across trials [26] , and although this could be achieved by performing sub-analyses, these methods require data to be available from several studies to enable reasonable estimation of the random effects. Meta-analysis methods are also available to synthesize individual patient and aggregate data, and enable adjustment for patient baseline characteristics [37] . Such methods would also allow differences in treatment effect due to differences in patient population to be accounted for, using a treatment-covariate interaction, but again these methods would be hindered by not having enough studies in the network to enable reasonable estimation of the random effects. The small number of studies and the need to account for endpoint definitions by performing additional sub-analyses (which would reduce the number of studies even further) made this method inappropriate in our case. An alternate method that could have been applied is the propensity score method of Signorovitch et al. [31] . This method adjusts for a predefined set of patient baseline characteristics, whereas our approach selects from such a set that best predicts the treatment effect. In the case of MS, in which studies have largely deduced potential treatment modifiers, our approach avoids overparameterization of the model and enables selection of a parsimonious model.
In this analysis, our modeling approach suggests that differences in average patient characteristics between the populations of the clinical trials of the oral therapies have a marginal impact on indirect comparisons of NEDA outcomes, because model outputs before adjustment for baseline covariates are similar to the outputs after adjustment. Taking previous DMT use as an example, the pooled FREEDOMS population had a higher rate of previous DMT use than the other trial populations. A smaller effect on achieving NEDA status might therefore be expected in this population than in one with less previous DMT use, and this was observed. Thus, adjusting for previous DMT use is likely to improve the comparative effectiveness of fingolimod relative to other therapies studied in a population with lower rates of DMT use. However, other differences in trial populations might lead to a greater effect on achieving NEDA status and the effects of different variables may eventually cancel each other out. Our methodology is indeed designed to improve on simply comparing raw event rates across studies. Our modeling approach showed that differences in trial methodologies had a greater impact on NEDA outcomes than differences in patient characteristics, thus highlighting the importance of adjusting for these methodological differences. The impact of these differences was exemplified by the RR predicted when using the DEFINE and CONFIRM approach of dealing with non-completers compared with using the TEMSO method.
This study assessed treatment efficacy using three composite measures of NEDA that were based on the absence of relapses, disability progression, Gd-enhancing T1 lesions, and new or newly enlarged T2 lesions. These individual component measures are wellestablished indicators of disease activity and are commonly assessed in clinical trials [17] [18] [19] [20] [21] [22] . As the effectiveness of treatments for MS increases, the composite endpoint of NEDA is becoming an important measure for clinicians and patients [16] . The use of these composite endpoints, however, does have some limitations because they do not take into account other potentially important indicators of disease activity, such as brain volume loss or cognitive function. In addition, some analytical adjustment to account for the dominance of one component measure may potentially be required. For example, one analysis has shown that the overall composite endpoint is driven to a large extent by MRI outcomes, with minimal contribution from clinical measures [32] . Finally, the number and timing of MRI scans were identical for the FREEDOMS trials and DEFINE and CONFIRM, but different for TEMSO. Imbalances in the timing or scheduling of scans could have an impact on MRI outcomes and the extent to which these outcomes contribute to the overall NEDA. Further research is needed to define the best combination of criteria that represents NEDA in MS and the best population in which to adjust the results, but this study provides a valuable exploration into the concepts.
Endpoint definitions also impact the results.
In an analysis of the CombiRx trial, which evaluated interferon beta-1a and glatiramer acetate in patients with RRMS, using a 1. 
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